



## Minutes

Date Wednesday, 14/05/2025

Time 10:00 AM

To Sub-Standing Committee

At Virtual, MS Teams

Subject AWERB Standing Committee

Our Ref Doc.UBS.AWERB.14.05.25

Present: [REDACTED]

Scientists in attendance for 1a) N/A

Apologies: [REDACTED]

Minutes: [REDACTED]

### 1. Project Licences

a) **Amendment:** [REDACTED] were also in attendance.

The committee discussed the following:

- Further clarification of specific procedures needed in the aims section of the Non-Technical Summary.
- Further explanation of the benefits that were in the researcher's presentation included in the Benefits section of the Non-Technical Summary.
- Clarification needed in the Project harms section of the Non-Technical Summary.
- Specific wording that was mentioned in the researcher's presentation should be included in the Reduction section of the Non-Technical Summary.
- Consideration should be given to whether additional refinements can be included in the Refinement section of the Non-Technical Summary.
- Consideration given to include specific treatments and additional clarification for the requested amendment in the scientific background section.
- In Protocols 4 and 5, Fate of animals. Inclusion of protocol 13 in the list of protocols to allow movement of animals.
- The inclusion of specific references in the Protocol details section of Protocol 13.
- Response changed to 'yes' in Protocol 13 in answer to the continued use question.
- Consideration given to a specific word in Protocol 13, Step 1. Title.
- Further description required for specific procedures planned as well as further consideration regarding anaesthetic codes. Further details regarding the monitoring and control sections or consideration given to whether specific procedures should be included as an independent step in step 1 of Protocol 13.
- Further information regarding adverse effects as well as clarification around specific procedures planned in step 1 of Protocol 13.



- Amendment of wording of specific effects in Protocol 13, Step 1.
- The inclusion of another measure for specific monitoring as well as further information around how the procedures will be refined to minimise the welfare costs for the animals in step 1 of Protocol 13.
- Removal or amendment of specific references in Protocol 13, Step 1. Consideration given to whether this should also be removed from other areas.
- The inclusion of a specific statement in Protocol 13, Step 1.
- Clarity around whether significant clinical signs are expected in Protocol 13, Step 1.
- Consideration of specific monitoring measures in Protocol 13, Step 1.
- Amend specific wording in Protocol 13, Step 1.
- Removal of specific wording in Protocol 13, Step 2 and consideration of whether it should also be removed from other areas of the project licence.
- Removal of specific wording in Protocol 13, Step 3.
- Consideration as to whether a baseline marker to measure specific adverse effects can be included in Protocol 13, Step 3.
- Review specific wording in Protocol 13, Step 3.

The committee agreed changes were needed before a draft is submitted to the Home Office

## 2. **Minutes of the last meeting** 12/03/25

The minutes from the previous meeting were approved.

## 3. **Retrospective Reviews [RR]**

a) [REDACTED]

The committee discussed the following:

- Further information regarding a specific animal in Section 2.3.
- Further clarification and information required around specific adverse effects listed in Section 2.3.
- Answers needed in Section 2.9.
- Consideration given to whether further explanation should be given in Section 3.2 or if it is more appropriate for the refinement question in Section 3.7.
- Further detail needed in Section 3.2.
- Further explanation required in Section 3.7.
- The answer to the question asked in Section 3.8 should be 'Yes'.

## 4. **Any other business**

There was no other business discussed.

## 5. **Date of next meeting:** 11/06/25